The worldwide prevalence of asthma is reaching epidemic proportions and continues to grow. Because asthma is characterized by a large and increasing number of affected individuals, by significant morbidity, and by important unmet needs, physicians and drug developers continue to strive to improve therapeutic approaches to asthma.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

Decision Resources, Inc., announces the publication of Asthma, a new study that evaluates current and emerging drugs to treat this chronic inflammatory disease. Drug development has focused largely on improving agents in the two broad therapeutic classes: bronchodilators and anti-inflammatory agents. More recently, a new area of development-combination agents-has emerged. Thought leaders interviewed for this study suggest that combination therapies may revolutionize asthma therapy during the next decade. Glaxo-SmithKline's Seretide (Advair in the United States), the first combination agent of this type, is well positioned to gain significant share and dominate this market throughout our 1999-2009 forecast period, reaching total annual sales of more than $1 billion by 2009 in the major markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). U.S. specialists are eager to try Advair in their patients, and very rapid growth and market success are anticipated upon the agent's U.S. approval.

AstraZeneca is also developing a combination agent-the long-acting beta2 agonist formoterol and the corticosteroid budesonide. RhuMAb-E25, an anti-IgE monoclonal antibody in development by Genentech/Hoffmann-La Roche and Tanox Biosystems/Novartis, is the novel therapeutic most advanced in development. Interviewed experts are very excited by its mechanism of action, and major-market peak-year sales of this drug, if approved, could reach $500 million.

Sales of drugs for the treatment of asthma in the major markets exceeded $4 billion in 1999. We estimate that this market will experience a significant annual growth rate of 7-8% per year, reaching a combined market size of close to $9 billion in 2009.

Asthma is part of the Immune and Inflammatory Disorders portfolio, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.

Contact: Frank Sama, 781.487.3753 (telephone), 781.487.5750 (fax), or sama@dresources.com (e-mail). In Europe, contact Ms. Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or fbidart@decisionresources.be (e-mail). In Japan, contact Ms. Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp (e-mail).

http://www.dresources.com/

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing industry trends in the international health care and pharmaceutical industries.

NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 201-369-3467

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, 781-487-3753, or
sama@dresources.com

New Decision Resources Study Evaluates the Potential Impact of Angiogenesis Inhibitors Over the Next Decade

View Now